|
| 37428131 | Geographic Atrophy Segmentation Using Multimodal Deep Learning. | Transl Vis Sci Technol | 2023 |
| 34265783 | Artificial intelligence-based predictions in neovascular age-related macular degeneration. | Curr Opin Ophthalmol | 2021 |
| 35106315 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection. | Open Forum Infect Dis | 2021 |
| 32393496 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection. | Antimicrob Agents Chemother | 2020 |
| 32621543 | Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection. | J Clin Pharmacol | 2020 |
| 28639229 | Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial. | Clin Pharmacokinet | 2018 |
| 28559255 | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers. | Antimicrob Agents Chemother | 2017 |
| 29269431 | Reply to Hunsberger and Memoli, "Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat". | Antimicrob Agents Chemother | 2017 |
| 28807912 | Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model. | Antimicrob Agents Chemother | 2017 |
| 27381392 | Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers. | Antimicrob Agents Chemother | 2016 |
| 27630240 | Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins. | J Virol | 2016 |
| 22328665 | Escherichia coli serotype O55:H7 diversity supports parallel acquisition of bacteriophage at Shiga toxin phage insertion sites during evolution of the O157:H7 lineage. | J Bacteriol | 2012 |
| 19118048 | rNAPc2 inhibits colorectal cancer in mice through tissue factor. | Clin Cancer Res | 2009 |
| 17456053 | The lymphoid cell surface receptor NTB-A: a novel monoclonal antibody target for leukaemia and lymphoma therapeutics. | Br J Haematol | 2007 |